- Home
- SMTK vs CLDI Comparison
SMTK vs CLDI Comparison
Compare SMTK & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- CLDI
- Stock Information
- Founded
- SMTK 2009
- CLDI 2014
- Country
- SMTK United Kingdom
- CLDI United States
- Employees
- SMTK N/A
- CLDI N/A
- Industry
- SMTK
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SMTK
- CLDI Health Care
- Exchange
- SMTK NYSE
- CLDI Nasdaq
- Market Cap
- SMTK 13.3M
- CLDI 12.0M
- IPO Year
- SMTK N/A
- CLDI N/A
- Fundamental
- Price
- SMTK $1.34
- CLDI $0.36
- Analyst Decision
- SMTK
- CLDI Strong Buy
- Analyst Count
- SMTK 0
- CLDI 1
- Target Price
- SMTK N/A
- CLDI $10.00
- AVG Volume (30 Days)
- SMTK 98.3K
- CLDI 456.3K
- Earning Date
- SMTK 05-13-2025
- CLDI 05-14-2025
- Dividend Yield
- SMTK N/A
- CLDI N/A
- EPS Growth
- SMTK N/A
- CLDI N/A
- EPS
- SMTK N/A
- CLDI N/A
- Revenue
- SMTK $105,000.00
- CLDI N/A
- Revenue This Year
- SMTK N/A
- CLDI N/A
- Revenue Next Year
- SMTK N/A
- CLDI N/A
- P/E Ratio
- SMTK N/A
- CLDI N/A
- Revenue Growth
- SMTK 854.54
- CLDI N/A
- 52 Week Low
- SMTK $1.00
- CLDI $0.34
- 52 Week High
- SMTK $8.16
- CLDI $3.89
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- CLDI 34.85
- Support Level
- SMTK N/A
- CLDI $0.34
- Resistance Level
- SMTK N/A
- CLDI $0.39
- Average True Range (ATR)
- SMTK 0.00
- CLDI 0.04
- MACD
- SMTK 0.00
- CLDI 0.00
- Stochastic Oscillator
- SMTK 0.00
- CLDI 15.45
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.